Increased SLE Flares with HCQ Reduction Concerns about the long-term safety of HCQ often results in dose reduction or drug discontinuation; yet a study shows that, for those in remission, HCQ taper/discontinuation resulted in a higher rate of SLE flares. https://t.co/BROdm7zLaw https://t.co/2cEDEc2eOn